Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis
DA Machalek, M Poynten, F Jin, CK Fairley… - The lancet …, 2012 - thelancet.com
Background Men who have sex with men (MSM) are at greatly increased risk of human
papillomavirus (HPV)-associated anal cancer. Screening for the presumed cancer …
papillomavirus (HPV)-associated anal cancer. Screening for the presumed cancer …
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …
vaccination was implemented. We did a systematic review and meta-analysis of the …
A review of clinical trials of human papillomavirus prophylactic vaccines
JT Schiller, X Castellsagué, SM Garland - Vaccine, 2012 - Elsevier
End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV)
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
S de Sanjose, WGV Quint, L Alemany… - The lancet …, 2010 - thelancet.com
Background Knowledge about the distribution of human papillomavirus (HPV) genotypes in
invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We …
invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We …
[HTML][HTML] Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
SM Garland, M Hernandez-Avila… - … England Journal of …, 2007 - Mass Medical Soc
Background A phase 3 trial was conducted to evaluate the efficacy of a prophylactic
quadrivalent vaccine in preventing anogenital diseases associated with human …
quadrivalent vaccine in preventing anogenital diseases associated with human …
[HTML][HTML] A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
EA Joura, AR Giuliano, OE Iversen… - … England Journal of …, 2015 - Mass Medical Soc
Background The investigational 9-valent viruslike particle vaccine against human
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised …
M Lehtinen, J Paavonen, CM Wheeler… - The lancet …, 2012 - thelancet.com
Background Cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is the surrogate
endpoint used in licensure trials of human papillomavirus (HPV) vaccines. Vaccine efficacy …
endpoint used in licensure trials of human papillomavirus (HPV) vaccines. Vaccine efficacy …
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a …
EA Joura, S Leodolter, M Hernandez-Avila… - The Lancet, 2007 - thelancet.com
Background Vulval and vaginal cancers among younger women are often related to
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence
CS Bradshaw, AN Morton, J Hocking… - The Journal of …, 2006 - academic.oup.com
Background We wished to determine recurrences of bacterial vaginosis (BV) after treatment
over the course of 12 months and to establish factors associated with recurrence Methods …
over the course of 12 months and to establish factors associated with recurrence Methods …
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine …
DR Brown, SK Kjaer, K Sigurdsson… - The Journal of …, 2009 - academic.oup.com
Abstract Background Human papillomavirus (HPV)–6/11/16/18 vaccine reduces the risk of
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …